The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
NCT ID: NCT00983034
Last Updated: 2009-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2006-03-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
NCT02933229
Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components
NCT06935955
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
NCT06050824
Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms
NCT07272681
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
NCT00990405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Membranous nephropathy
Patients with primary membranous nephropathy diagnosed by biopsy
lansoprazole, amoxicillin, clarithromycin
lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
IgA nephropathy
Patients with IgA nephropathy diagnosed by biopsy
lansoprazole, amoxicillin, clarithromycin
lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Focal segmental glomerulosclerosis
Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
lansoprazole, amoxicillin, clarithromycin
lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lansoprazole, amoxicillin, clarithromycin
lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nondiabetic patients
* Patients with primary glomerulonephritis
* Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy
* Glomerular filtration rate \> 30 mL/min
* Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study
Exclusion Criteria
* Glomerular filtration rate \< 30 mL/min
* Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study
* Patients with a history of gastric surgery
* Patients without an informed consent
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Division of Nephrology, Department of Intenal Medicine, Istanbul Faculty of Medicine, Istanbul University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yasar Caliskan, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Berna Yelken, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Halil Yazici, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Mehmet S Sever, Prof MD
Role: STUDY_DIRECTOR
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Caliskan B, Yazici H, Caliskan Y, Ozluk Y, Gulluoglu M, Kilicaslan I, Turkmen A, Sever MS. The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis. Int J Nephrol. 2014;2014:180690. doi: 10.1155/2014/180690. Epub 2014 Feb 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20061976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.